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IORT staff and could provide a provisional plan that includes 
also DVH and MU calculation.  
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Purpose or Objective: Monte Carlo (MC) recalculation of 
spot-scanning proton therapy treatment plans can provide an 
independent verification of monitor units required for 
delivery, and reduce the time treatment rooms need to be 
reserved for patient specific QA. We describe the 
development of such a MC verification system for a clinical 
facility. 
 
Material and Methods: Realistic clinical beam models were 
developed by matching simulations (using GATE/GEANT4) to 
measurements made in a clinical beamline. They consist of a 
tuned physics list, a lookup table relating each of the 115 
nominal beam energies to a tuned spot energy (mean and 
standard deviation) and phase space parameters which allow 
spot sizes to be properly modeled for any combination of 
energy and nozzle extension. For all beam energies 
simulations accurately reproduce both integral depth dose 
profiles (>97% of data-points pass a local gamma analysis at 
2%/2mm) and lateral profiles measured in air and in solid 
water (with a 0.2 mm maximum difference). The model was 
further validated against a series of simple test plans which 
were optimized in the clinical Treatment Planning System 
(TPS) to produce uniform dose volumes at various depths in 
water.The automated MC system can process, simulate and 
analyse treatment plans without user input once it receives 
the TPS files. 
 
Results: 
 
 
 
The system was tested for a three field (11k spot) base of 
skull treatment plan computed in a patient CT dataset. 
Simulations were split into 40 calculations over a 10 quad-
core CPU cluster, requiring <30 minutes to achieve dosimetric 
uncertainties (within the 90% isodose volume) of <1%. The 
figure demonstrates the broad agreement between the TPS 
(left) and the MC simulation (right). The local gamma pass 
rate between the two (bottom) is 97% at 4%/4mm (green 
voxels pass, red / blue voxels fail). This should be 
interpreted in the context of this being a highly 
inhomogeneous target site: Differences occurred only in 
heterogeneous regions where the TPS’s analytical dose 
calculation would be expected to model dose deposition less 
accurately than MC systems. For example, the MC simulations 
predict a lower dose around the sinus air cavities than the 
TPS. 
 
Conclusion: We have demonstrated that the MC verification 
system can accurately reproduce the dose distribution 
predicted by a clinical TPS. Further validation work is 
ongoing using a variety of plans and phantom measurements. 
Once clinically commissioned, the system can be used as an 
independent dose checker, reducing on-set verification time. 
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Purpose or Objective: To establish the workflow & 
methodology and to perform an experimental validation of 
treatment plan conversion from Tomotherapy HD machine 
(Accuray) using dynamic jaws to a True Beam (Varian) Linac. 
For this purpose, the RayStation (RS) TPS using fallback 
planning (RFP) is currently tested. An end-to-end set of 
phantom configurations of increasing complexity are 
presented. The ultimate goal is to validate this process in 
order to minimize the impact of machine downtime on 
patient treatments. 
 
Material and Methods: Four phantom based treatment plans 
were generated in the Tomotherapy Planning Station. These 
plans were mimicked with RFP for the TrueBeam using X6-FFF 
dual-arc VMAT. The first three cases planned on the Cheese 
Phantom (Std. Imaging) consisted of 1 to 4 target dose levels 
and 3 OARs, using heterogeneous inserts for the last one. The 
4th case was an integrated boost H&N treatment with 3 
target dose levels planned on an anthropomorphic phantom 
(H&N, IBA). Original Helical Tomotherapy (HT) and RS 
fallback plans were delivered respectively on each machine. 
Ion chamber (A1SL, Std. Imaging) and Gafchromic EBT3 (ISP) 
films were used to measure absolute and planar doses. First, 
for both machines beam delivery vs. treatment plan was 
evaluated as a baseline for absolute dose, gamma (γ) passing 
rate (criteria 3%/3mm) and overall uncertainties. Secondly, 
in order to ensure that the difference between the two 
calculated dose distributions (TPS_TOMO / TPS_RAYSTATION) 
matched the differences between the two measured film 
dose distributions (Film_TOMO / Film_RAYSTATION), a γ 
difference (5%/5mm) was performed. 
 
 
 
Results: First, gamma evaluation was (99.1±0.6)% for HT and 
(99.5±0.4)% for RS fallback plans while absolute dose 
differences between calculations and ion chamber 
measurements were respectively 0.9% for HT and -0.7% for RS 
on average for all end-to-end tests. Secondly, average γ 
difference between calculated doses TPS_TOMO / 
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TPS_RAYSTATION and measured planar doses Film_TOMO / 
Film_RAYSTATION was (0.3±0.2)%. 
 
 
 
Conclusion: Raystation fallback planning is an advanced 
feature that allows switching patient plans between 
alternative treatment machines and techniques. This could 
be useful to reduce impact of machine downtime on patient 
treatments. However, this process could introduce potential 
risks as distinct TPS and beam deliveries are involved. The 
results presented here show that a difference between 
calculated HT and mimicked RS fallback plans match the 
measured differences found throughout the end-to-end tests. 
Results based on a 5%/5mm tolerance show that we can 
expect at most 0.3% agreement from the difference between 
original and fallback plans displayed by the RS TPS. Further 
work will involve the study of clinical plans on various tumors 
sites. 
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Purpose or Objective: Monte Carlo (MC) approach is 
considered the gold standard method to perform absorbed 
dose calculations in external radiotherapy[1], because it 
provides the most detailed and complete description of 
radiation fields and particle transport in tissues. Several 
codes are available and recently a new MC Penelope based 
code and graphic platform named PRIMO was developed [2]. 
PRIMO has a user-friendly approach, a suitable and 
competitive characteristic for clinical activity. Nevertheless, 
advanced features such as IMRT are not introduced yet. This 
work is a preliminary study for the PRIMO software as a tool 
for MC based quality control of IMRT treatment. 
 
Material and Methods: The simulated beam parameters of a 
Varian CLINAC 2300 were adjusted based on measurements in 
a water tank for 6 MeV energy and 10x10 cm² field. The 
water tank was divided in 81x81x155 voxels with dimensions 
of 2x2x2 mm³. The Gamma Function (GF) was used for 
agreement assessment and a phase-space was obtained above 
the MLC. A solid water phantom with a PTW OCTAVIUS® 729 
2D ionization chamber array inserted was imaged by a CT 
scan and used in PRIMO. A dynamic IMRT plan was calculated 
by the Eclipse™ TPS and irradiated. The LINAC DynaLog files 
were analysed and the dynamic delivery was divided into 
series of static fields in PRIMO. MATLAB was used to analyse 
the PRIMO output and to create images of dose distributions 
at specific locations. The simulated dose at the ion chamber 
matrix position in the phantom was compared with the 
matrix measurement using the 2D GF through the PTW 
Verisoft program. 
 
Results: The best agreement for the beam parameters of the 
LINAC numerical model was obtained with initial electron 
energy of 5.9±0.2 MeV and beam divergence of 1.5°. The 
gamma function analysis (2%, 2mm) showed that 97% of the 
points was lower than 1, confirming the good agreement with 
the experimental data. For the IMRT plan, the measured and 
simulated dose distributions at the ion chamber matrix (fig 
1A-B) show good agreement, as the gamma points lower than 
1 were 96% (fig 1C). 
 
 
Conclusion: This preliminary study shows that an IMRT plan 
was successfully simulated through PRIMO with acceptable 
concordance with the experimental results. Even though 
further studies on more complex treatments are still 
required, the results confirm PRIMO as a promising tool for 
IMRT simulation in clinical environment. 
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Purpose or Objective: The aim of this paper is to evaluate 
the EPID detector sensitivity and specificity for in vivo 
dosimetry of VMAT treatments to identify dosimetric and 
geometric errors and anatomical variations. 
 
Material and Methods: Measurements were performed by 
using TrueBeam STx accelerator equipped with EPID aSi1000 
(Varian, Palo Alto, CA) and PerFraction (PF) software (Sun 
Nuclear Corporation, Melbourne, FL). PF is a commercial 
EPID-based dosimetry software, which allows performing 
transit dosimetry, to provide an independent daily 
verification of the treatment. Performance of the EPID 
detector and of the PF software on anthropomorphic 
phantom was studied, simulating 17 perturbations of the 
reference VMAT plan. Systematic variations in dose values 
(1%-5% output variation), shifts (2,5-11 mm in anterior 
direction), anatomical variations (adding bolus over 
phantom), and MLC positioning (locked leaf position for 
different arc extensions) were applied. The difference in 
local and global gamma pass rate (%GP) between the no-error 
and error-simulated measurements with 1%/1mm, 2%/2 mm 
and 3%/3 mm tolerances was calculated. The clinical impact 
of these errors was also analyzed through the calculation of 
the difference between the reference DVH and the perturbed 
DVH (%DE). We defined as clinically meaningful a variation 
higher than 3% between calculated and perturbated doses. A 
value of %GP equal to 95% and 90% and %DE equal to 3% were 
used as thresholds to calculate sensitivity and specificity.  
 
Results: Repeatability and reproducibility of no-error 
measurements were excellent with %GP=100% for all gamma 
